Merck Settles Gardasil Lawsuits for More Than $50 Million: What the Deal Covers and What It Does Not Admit

Merck has agreed to settle most of the lawsuits over its Gardasil human papillomavirus vaccine, ending a long-running piece of product liability litigation without admitting that the vaccine caused harm. The settlement, reported by Insurance Journal on June 8, 2026, is for more than $50 million according to people familiar with the matter. This article summarises that report. An earlier version of this article described the claims in a way that implied a federal summary judgment ruling in March 2025 and gave details of appeals that the report does not support. The report describes a ruling by a North Carolina judge, and those details have been corrected here. The report does not discuss insurance coverage, so this article does not attempt to say who is paying beyond the company's statements.

The numbers first. Merck will pay more than $50 million to settle more than 200 cases, according to people familiar with the matter. The company says the amount is considerably less than its anticipated costs of defending the cases, and it calls the payment not material to the company. Those statements are consistent with a business decision to end the litigation, not an admission that the claims had merit. Merck says it decided to end the litigation in its entirety by settling, and officials say the deal will only be finalised if enough people who received Gardasil sign on. In its February annual report, Merck said it had entered into a proposed agreement in October 2025 that still needed additional steps.

What cases does it cover? The settlement covers all Gardasil litigation except one case, according to the report. The more than 200 cases in North Carolina were dismissed last year by a judge who found them preempted by the Food and Drug Administration's approval of the vaccine's labelling, and who also found the plaintiffs' expert evidence insufficient. Preemption is a legal doctrine under which federal law overrides state-law claims; in drug cases, defendants argue that they could not have changed the label without FDA approval, so a claim that the label was inadequate cannot succeed under state law. Those dismissed cases are included in the deal. The other major piece is Robi v. Merck, case number BC628589, in the Superior Court of California for the County of Los Angeles. The plaintiff, Jennifer Robi, says Gardasil, which she received as a teenager, caused a heart ailment that left her in a wheelchair. The case was set for trial next month, and it could have produced the first jury decision against Merck over the vaccine. According to the report, the Los Angeles lawyer for the plaintiff declined to comment.

The report also mentions a connection that has drawn attention. Robert F. Kennedy Jr., the US Secretary of Health and Human Services, is a former plaintiffs' lawyer who helped prepare Robi's claims before becoming secretary in 2025. He was set to receive 10% referral fees on successful Gardasil suits but has waived them. The report notes that in March a judge temporarily blocked his effort to reduce the list of recommended childhood vaccines, including a proposal to cut the recommended HPV doses for young people from up to three to one, and that Kennedy and the group Children's Health Defense are appealing. We note these points as reported and do not draw conclusions about them.

Merck's position on safety is consistent. It has consistently denied that the vaccine causes dangerous side effects, and it says its research continues to support the safety and efficacy of its HPV vaccines. The settlement does not require a finding that the vaccine was harmful. Gardasil prevents HPV infection, which researchers have linked to cervical cancer. The vaccine has been approved in about 150 countries since its introduction 20 years ago, and Merck says more than 900 million doses of Gardasil and Gardasil 9 have been distributed worldwide.

On the business side, Gardasil sales reached $8.9 billion in 2023. They have declined over the last two years because of low-cost competitors in China, after strong growth in the early 2020s. For Merck, which is based in Rahway, New Jersey, the settlement removes a source of uncertainty and cost from a product whose revenue is under pressure.

Why does this matter to the insurance and risk community? Mass tort litigation, where many plaintiffs sue over the same product, is a significant driver of liability costs for manufacturers and their insurers, and it features in the discussion of social inflation, the rise in claim costs from legal and social factors. The settlement illustrates three features of such disputes. Defendants with strong legal defences, such as preemption, may still settle to avoid the unpredictability of a jury trial. Settlement amounts can be modest compared with the cost of defending cases over many years. And the outcome of a few bellwether cases can influence the value of hundreds of others. Our coverage this week of the Swiss Re Institute's report on UK liability claims shows similar themes in another jurisdiction.

For patients and parents, the settlement says nothing about whether to vaccinate; medical guidance on HPV vaccination comes from public health authorities and doctors. For investors, the key points are the size of the payment relative to Merck's earnings and the risk that remains from the one case not covered. Readers should consult Merck's regulatory filings for the company's own description of the matter.